Coronavirus Disease 2019: Considerations for Health Technology Assessment From the National Centre for Pharmacoeconomics Review Group - Leahy, Joy; Hickey, Conor; McConnell, David; Cassidy, Owen; Trela-Larsen, Lea; Barry, Michael; Tilson, Lesley; McCullagh, Laura (Value in health, 2020)
Keywords: Advisory Committees; Applicants; Betacoronavirus; budget impact; Budgets; Clinical assessment; Clinical research; Clinical trials; Coronavirus Infections - drug therapy; Coronaviruses; cost-effectiveness; COVID-19; Discontinued; Economics; Economics, Pharmaceutical; evidence synthesis; Extrapolation; Health care expenditures; Health technology assessment; Humans; Internal Medicine; Medical technology; Medical treatment; Pandemics; Patients; Pharmacoeconomics; Pharmacology; Pneumonia, Viral - drug therapy; Public Health; Quality of Life; SARS-CoV-2; Sensitivity analysis; Technology assessment; Technology Assessment, Biomedical; Themed Section: COVID-19; treatment discontinuation; treatment effect; Treatment Outcome; Uncertainty; Withholding Treatment; COVID-19; health technology assessment; cost-effectiveness; extrapolation; treatment effect; treatment discontinuation; evidence synthesis; budget impact